GLAND vs INNOVACAP: Stock Comparison
GLAND PHARMA is the larger company by market capitalisation. GLAND PHARMA shows a higher dividend yield, lower leverage and a higher ROCE, while INNOVA CAPTAB shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLAND leads 8; INNOVACAP leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLAND | INNOVACAP |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLAND | INNOVACAP |
|---|---|---|
| Live Price | ₹3,054.5 | ₹1,025.8 |
| Day Change | -0.65% | -2.41% |
| Volume | 40,403 | 9,658 |
| 52-Week High | ₹3,171 | ₹1,353.5 |
| 52-Week Low | ₹1,573.6 | ₹622 |
| Distance from 52W High | -3.67% | -24.21% |
Valuation
| Metric | GLAND | INNOVACAP |
|---|---|---|
| Market Cap | ₹50,922 Cr | ₹5,882 Cr |
| P/E Ratio | 44.78x | 38.26x |
| P/B Ratio | 4.88x | 5.53x |
| EPS | ₹68.47 | ₹26.91 |
| Book Value | ₹628.68 | ₹190.62 |
| Dividend Yield | 0.66% | 0.38% |
Growth
| Metric | GLAND | INNOVACAP |
|---|---|---|
| Revenue Growth (TTM YoY) | 22.3% | 42.3% |
| EPS Growth (TTM YoY) | 96.4% | 28.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | GLAND | INNOVACAP |
|---|---|---|
| ROE | 12.02% | 12.92% |
| ROCE | 17.2% | 10.77% |
| Net Margin | 16.18% | 8.65% |
| Operating Margin | 38.8% | 12.59% |
| Debt to Equity | 0x | 0.32x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | GLAND | INNOVACAP |
|---|---|---|
| Promoter Holding | 45.75% | 50.9% |
| FII Holding | 10.36%▲ 1.62 pp | 0.84%▲ 0.5 pp |
| DII Holding | 33.21%▲ 2.77 pp | 19.16%▼ 0.76 pp |
| Public Holding | 10.66%▲ 1.61 pp | 29.09%▲ 0.25 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLAND PHARMA and INNOVA CAPTAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.